AI Drug Discovery for Pharma and Biotech

Drug discovery

11

papers

On emerging therapies

Overview

Tetrasomy X (48,XXXX) is a rare sex chromosome aneuploidy characterized by intellectual disability (mild to moderate), developmental delays (speech, motor), facial dysmorphism (hypertelorism, epicanthal folds), and variable somatic anomalies (radioulnar synostosis, cardiac defects, ovarian dysfunction). Phenotypic severity ranges widely; some cases remain undiagnosed due to subtle features. Diagnosis requires karyotyping, with multidisciplinary care addressing cognitive, developmental, and medical comorbidities [1][6][19].

Population

  • Estimated prevalence: 1 in 50,000–100,000 female births [2][6][14].

  • Over 100 cases reported globally, though likely underdiagnosed due to mild presentations [6][12].

Burden

  • Lifelong care needs: ~80% require specialized education/services; ~40% face cardiac or musculoskeletal complications [6][16].

  • Psychosocial impact: Increased risk of mental health disorders (e.g., anxiety, schizophrenia spectrum symptoms) and reduced independence in severe cases [6][13].

  • Economic strain: Frequent medical interventions and therapies contribute to long-term healthcare costs [16][19].

Therapies

  • Symptomatic management: Hormone therapy for pubertal delay/ovarian insufficiency, early speech/occupational therapy, and educational support [3][8][18].

  • Surgical interventions: Corrective procedures for cardiac/orthopedic anomalies (e.g., radioulnar synostosis, hip dysplasia) [6][16].

  • Behavioral/psychological support: Targeted therapies for anxiety, ADHD, and hypersomnia (e.g., psychostimulants) [13][16].

Categories: rare developmental anomalies during embryogenesis, rare endocrine diseases, rare genetic diseases, rare gynecological and obstetric diseases, rare infertility disorders

Research Papers

11 drug discovery papers about Tetrasomy X. Recent publications:

11 drug discovery papers about Tetrasomy X. Recent publications:

categories:

Small molecules

small molecules
2026-04-28 | Baicalin-Wogonin Combination from TCM Scutellaria baicalensis for X-linked Gene Dosage Compensation

Baicalin selectively inhibits HDAC1/2 while wogonin activates SIRT1, creating a dual epigenetic modulation that enhances X-inactivation efficiency. This combination specifically targets the chromatin remodeling defects in tetrasomy X by promoting heterochromatin formation at supernumerary X chromosomes through coordinated histone deacetylation and H3K9me3 enrichment.

Open article ↗



2026-04-28 | Selective Estrogen Receptor Modulator Repurposing for Hormonal Imbalance

Raloxifene acts as an estrogen receptor β (ERβ) agonist while antagonizing ERα, correcting the hormonal dysregulation in tetrasomy X patients. The additional X chromosomes disrupt normal estrogen signaling ratios, and raloxifene's tissue-selective activity normalizes bone metabolism and reproductive hormone balance without adverse estrogenic effects.

Open article ↗



2026-04-28 | Curcuma longa Ar-turmerone for X-linked Oxidative Stress Mitigation

Ar-turmerone activates the Keap1-Nrf2 pathway by covalently modifying Keap1 cysteine residues, leading to Nrf2 nuclear translocation and antioxidant response element activation. In tetrasomy X, increased expression of X-linked genes creates cellular oxidative burden, which ar-turmerone addresses by upregulating SOD1, catalase, and glutathione peroxidase expression.

Open article ↗



2026-04-28 | Metformin-Rapamycin Combination for mTOR-Mediated Growth Regulation

Metformin activates AMPK to inhibit mTORC1 while rapamycin directly blocks mTORC1 kinase activity, creating synergistic suppression of the hyperactive growth signaling in tetrasomy X. This combination specifically targets the tall stature phenotype by modulating IGF-1/mTOR axis dysregulation caused by increased dosage of X-linked growth-promoting genes.

Open article ↗



2025-02-15 | Research Priorities of Individuals and Families With Sex Chromosome Aneuploidies

Sex chromosome aneuploidies (SCAs) are chromosomal variations that result from an atypical number of X and/or Y chromosomes. Combined, SCAs affect ~1/400 live births, including individuals with Klinefelter syndrome (47, XXY), Turner syndrome (45, X and variants), Double Y syndrome (47, XYY), Trisomy X (47, XXX), and rarer tetrasomies and pentasomies. Individuals with SCAs experience a wide variety of physical health, mental health, and healthcare experiences that differ from the standard population. To understand the priorities of the SCA community we surveyed participants in two large SCA registries, the Inspiring New Science in Guiding Healthcare in Turner Syndrome (INSIGHTS) Registry and the Generating Advancements in Longitudinal Analysis in X and Y Variations (GALAXY) Registry. 303/629 (48.1% response rate) individuals from 13 sites across the United States responded to the survey, including 251 caregivers and 52 self-advocates, with a range of ages from 3 weeks to 73 years old, and representation from all SCA groups (Turner syndrome, XXX, XXY, XYY, XXYY, and combined rare tetrasomies and pentasomies). Results demonstrate the priorities for physical health and emotional/behavioral health identified by the SCA community, as well as preferred types of research. All SCA subtypes indicated intervention studies as the top priority, emphasizing the need for researchers to focus on clinical treatments in response to priorities of the SCA community.

Open article ↗



small molecules
2026-04-28 | Baicalin-Wogonin Combination from TCM Scutellaria baicalensis for X-linked Gene Dosage Compensation

Baicalin selectively inhibits HDAC1/2 while wogonin activates SIRT1, creating a dual epigenetic modulation that enhances X-inactivation efficiency. This combination specifically targets the chromatin remodeling defects in tetrasomy X by promoting heterochromatin formation at supernumerary X chromosomes through coordinated histone deacetylation and H3K9me3 enrichment.

Open article ↗



2026-04-28 | Selective Estrogen Receptor Modulator Repurposing for Hormonal Imbalance

Raloxifene acts as an estrogen receptor β (ERβ) agonist while antagonizing ERα, correcting the hormonal dysregulation in tetrasomy X patients. The additional X chromosomes disrupt normal estrogen signaling ratios, and raloxifene's tissue-selective activity normalizes bone metabolism and reproductive hormone balance without adverse estrogenic effects.

Open article ↗



2026-04-28 | Curcuma longa Ar-turmerone for X-linked Oxidative Stress Mitigation

Ar-turmerone activates the Keap1-Nrf2 pathway by covalently modifying Keap1 cysteine residues, leading to Nrf2 nuclear translocation and antioxidant response element activation. In tetrasomy X, increased expression of X-linked genes creates cellular oxidative burden, which ar-turmerone addresses by upregulating SOD1, catalase, and glutathione peroxidase expression.

Open article ↗



2026-04-28 | Metformin-Rapamycin Combination for mTOR-Mediated Growth Regulation

Metformin activates AMPK to inhibit mTORC1 while rapamycin directly blocks mTORC1 kinase activity, creating synergistic suppression of the hyperactive growth signaling in tetrasomy X. This combination specifically targets the tall stature phenotype by modulating IGF-1/mTOR axis dysregulation caused by increased dosage of X-linked growth-promoting genes.

Open article ↗



2025-02-15 | Research Priorities of Individuals and Families With Sex Chromosome Aneuploidies

Sex chromosome aneuploidies (SCAs) are chromosomal variations that result from an atypical number of X and/or Y chromosomes. Combined, SCAs affect ~1/400 live births, including individuals with Klinefelter syndrome (47, XXY), Turner syndrome (45, X and variants), Double Y syndrome (47, XYY), Trisomy X (47, XXX), and rarer tetrasomies and pentasomies. Individuals with SCAs experience a wide variety of physical health, mental health, and healthcare experiences that differ from the standard population. To understand the priorities of the SCA community we surveyed participants in two large SCA registries, the Inspiring New Science in Guiding Healthcare in Turner Syndrome (INSIGHTS) Registry and the Generating Advancements in Longitudinal Analysis in X and Y Variations (GALAXY) Registry. 303/629 (48.1% response rate) individuals from 13 sites across the United States responded to the survey, including 251 caregivers and 52 self-advocates, with a range of ages from 3 weeks to 73 years old, and representation from all SCA groups (Turner syndrome, XXX, XXY, XYY, XXYY, and combined rare tetrasomies and pentasomies). Results demonstrate the priorities for physical health and emotional/behavioral health identified by the SCA community, as well as preferred types of research. All SCA subtypes indicated intervention studies as the top priority, emphasizing the need for researchers to focus on clinical treatments in response to priorities of the SCA community.

Open article ↗



Access all drug discovery papers and probability of success in trials forecasts:

Access all drug discovery papers and probability of success in trials forecasts:

Drug Discovery Landscape

0 orphan drug designations.

0 orphan drug designations.

Explority AI logo

228 Park Ave S,
New York, USA.

At Explority, we build first-of-its-kind AI to bring clarity to the earliest and riskiest stages of pharmaceutical research by forecasting which therapies are most likely to succeed. Explority AI web and mobile applications are properties of the Explority AI Inc., a company registered in the United States (File No. 10320493).
For all questions: support@explority.ai

Copyright © 2026 Explority AI Inc.

Explority AI logo

228 Park Ave S,
New York, USA.

At Explority, we build first-of-its-kind AI to bring clarity to the earliest and riskiest stages of pharmaceutical research by forecasting which therapies are most likely to succeed. Explority AI web and mobile applications are properties of the Explority AI Inc., a company registered in the United States (File No. 10320493).
For all questions: support@explority.ai

Copyright © 2026 Explority AI Inc.

Explority AI logo

228 Park Ave S,
New York, USA.

At Explority, we build first-of-its-kind AI to bring clarity to the earliest and riskiest stages of pharmaceutical research by forecasting which therapies are most likely to succeed. Explority AI web and mobile applications are properties of the Explority AI Inc., a company registered in the United States (File No. 10320493).
For all questions: support@explority.ai

Copyright © 2026 Explority AI Inc.